Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of subcutaneous SHR-1314 in lupus nephritis
CTR20211337Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vunakizumab in lupus nephritis (LN), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jun 2021; status: active.
02
Drugs
vunakizumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20211337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211337.